Vertex, which already has a research site in Oxford, hopes the tie-up will advance its efforts to develop transformation precision drugs for people with serious diseases. Using its analysis ...

While the company did not specify the module’s conversion efficiency, its power output exceeds that of a number of the company’s other products, including its Vertex N series of modules ...

OXB, formerly Oxford Biomedica, is a rising gene and cell ... The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Vertex Pharmaceuticals. Views expressed on the companies mentioned ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...